Is the gastric sleeve safe? It is a question asked by thousands of people across the UK each year who are considering bariatric surgery as a treatment for severe obesity. Sleeve gastrectomy is now the most commonly performed weight-loss operation in the UK, supported by NICE Clinical Guideline CG189 and NHS England commissioning policy. This article examines the clinical evidence, safety profile, risks, patient eligibility criteria, and long-term outcomes of gastric sleeve surgery, drawing on UK registry data, BOMSS guidance, and current NHS practice to help you make a fully informed decision.

What Is Gastric Sleeve Surgery and How Is It Performed?

Gastric sleeve surgery removes 75–80% of the stomach laparoscopically, leaving a narrow sleeve that restricts food intake and reduces ghrelin, the hunger hormone. It is the most commonly performed bariatric procedure in the UK.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gastric sleeve surgery, formally known as sleeve gastrectomy, is a type of bariatric (weight-loss) surgery in which approximately 75–80% of the stomach is surgically removed, leaving a narrow, sleeve-shaped tube. Unlike gastric bypass, the procedure does not reroute the intestines, making it anatomically simpler whilst still producing significant and sustained weight loss. According to the National Bariatric Surgery Registry (NBSR), sleeve gastrectomy is now the most commonly performed bariatric procedure in the UK.

The operation is almost always performed laparoscopically — that is, using small incisions and a camera — under general anaesthesia. A surgeon uses a stapling device to divide and remove the larger curvature of the stomach. The remaining sleeve is then sealed with surgical staples. Most patients are admitted to hospital for one to three nights. Return to desk-based work is typically possible within one to two weeks, whilst more physically demanding activities may require four to six weeks' recovery; individual timelines vary by centre and patient circumstances, and your surgical team will provide personalised guidance aligned with NHS and British Obesity and Metabolic Surgery Society (BOMSS) recommendations.

The mechanism by which gastric sleeve surgery promotes weight loss is twofold:

• Restriction: The dramatically reduced stomach capacity limits the volume of food that can be consumed at any one time.

• Hormonal change: Removal of the fundus of the stomach significantly reduces levels of ghrelin, the hormone primarily responsible for stimulating hunger, which helps reduce appetite over the longer term.

Because the pylorus (the valve controlling stomach emptying) is preserved, the procedure maintains a more natural digestive process compared with some other bariatric operations. This makes it a widely chosen option within NHS bariatric programmes and private surgical centres across the UK.

Safety Profile and Clinical Evidence for Gastric Sleeve Surgery

UK NBSR data show a 30-day mortality rate of 0.05–0.2% in accredited centres, and NICE CG189 recognises sleeve gastrectomy as a clinically validated intervention for severe obesity within a specialist multidisciplinary setting.

Gastric sleeve surgery has an established and broadly favourable safety profile when performed in appropriately selected patients by experienced surgical teams. Contemporary UK data from the National Bariatric Surgery Registry (NBSR) indicate a 30-day mortality rate in the region of 0.05–0.2% in accredited UK centres, reflecting improvements in patient selection, surgical technique, and perioperative care over recent years.

The evidence base has matured considerably since the procedure became widespread in the early 2000s. NBSR data and international registry evidence confirm that serious complications are relatively uncommon when surgery is carried out in accredited centres following established protocols. NICE Clinical Guideline CG189 and NHS England's service specification for severe and complex obesity both recognise bariatric surgery, including sleeve gastrectomy, as a clinically validated intervention for severe obesity when delivered within a specialist multidisciplinary setting.

Key safety considerations supported by evidence include:

• Short-term safety: Laparoscopic technique reduces wound complications, blood loss, and recovery time compared with open surgery.

• Comorbidity improvement: Evidence from the NBSR and NICE CG189 demonstrates significant improvement or remission of obesity-related conditions including type 2 diabetes, hypertension, obstructive sleep apnoea, and metabolic dysfunction-associated steatotic liver disease (MASLD, previously termed non-alcoholic fatty liver disease or NAFLD) following sleeve gastrectomy.

• Comparative safety: When compared with Roux-en-Y gastric bypass, sleeve gastrectomy generally carries a lower risk of nutritional deficiencies and dumping syndrome, though it may be associated with a higher rate of gastro-oesophageal reflux disease (GORD) in some patients, as noted in BOMSS position statements.

It is important to note that 'safe' does not mean 'without risk'. All surgical procedures carry inherent risks, and the decision to proceed should always involve a thorough multidisciplinary assessment.

Risks, Complications, and How They Are Managed on the NHS

Short-term risks include staple line leak (0.5–2%), bleeding, and DVT; long-term risks include GORD, nutritional deficiencies, and weight regain. Complications are managed within specialist NHS bariatric units following BOMSS guidance.

As with any major surgical procedure, gastric sleeve surgery carries a range of potential risks, which can be broadly categorised as short-term (perioperative) and long-term complications. Understanding these risks is an essential part of informed consent.

Short-term risks include:

• Staple line leak (occurring in approximately 0.5–2% of cases in contemporary UK and European series) — the most serious early complication, requiring prompt surgical or radiological intervention

• Bleeding from the staple line or surrounding vessels

• Deep vein thrombosis (DVT) or pulmonary embolism — mitigated by anticoagulation therapy and early mobilisation

• Infection, including wound infection or intra-abdominal abscess

• Dehydration, particularly in the early postoperative period if fluid intake is inadequate

• Anaesthetic complications, which are higher in patients with significant obesity-related comorbidities

Longer-term risks include:

• Gastro-oesophageal reflux disease (GORD): A notable concern, as the procedure can worsen or trigger acid reflux in some patients. Those with pre-existing GORD or Barrett's oesophagus may be advised to consider gastric bypass instead.

• Nutritional deficiencies: Particularly of vitamin B12, iron, vitamin D, calcium, and folate. In line with BOMSS postoperative monitoring and supplementation guidelines (2020), lifelong supplementation is recommended — typically a complete multivitamin and mineral supplement, vitamin D with or without calcium, and iron where indicated, with B12 managed according to local protocol. Blood tests are recommended at 3, 6, and 12 months post-surgery, then annually thereafter.

• Stricture or stenosis: Narrowing of the sleeve, which may cause persistent vomiting or difficulty swallowing and may require endoscopic or surgical treatment.

• Gallstones: Rapid weight loss increases the risk of gallstone formation. Some centres prescribe ursodeoxycholic acid prophylactically in the first six months; discuss this with your surgical team.

• Weight regain: Some patients experience gradual weight regain after several years, particularly without sustained dietary and behavioural changes.

• Sleeve dilation: Over time, the remaining stomach may stretch, reducing the restrictive effect.

• Hair thinning: Temporary hair loss (telogen effluvium) is common in the first few months and usually resolves with adequate nutrition.

• Gastritis or marginal ulceration: Inflammation of the sleeve lining, which may require medication.

• Hypoglycaemia or dumping-type symptoms: Less common than after gastric bypass but can occur.

• Incisional hernia: A recognised longer-term surgical complication.

Red-flag symptoms — seek urgent help: Contact your bariatric unit or attend the emergency department promptly if you experience severe abdominal pain, persistent vomiting or inability to keep fluids down, fever, chest pain, breathlessness, rapid heart rate, calf pain or swelling, difficulty swallowing, or if you pass black or bloody stools. Call 999 immediately for life-threatening symptoms such as collapse, severe chest pain, or difficulty breathing. If you are unsure, contact NHS 111 for advice.

If you suspect a problem related to a surgical device used during your procedure, you can report this via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

On the NHS, complications are managed within specialist bariatric units with access to dietitians, specialist nurses, and surgeons, in line with NHS England service specifications and BOMSS guidance.

Who Is Suitable for Gastric Sleeve Surgery in the UK?

NICE CG189 recommends surgery for adults with a BMI of 40 kg/m² or above, or 35–39.9 kg/m² with a significant comorbidity, following unsuccessful non-surgical interventions and a full multidisciplinary team assessment.

Patient selection is a critical determinant of both safety and outcome in gastric sleeve surgery. In the UK, eligibility criteria are guided by NICE Clinical Guideline CG189 (Obesity: identification, assessment and management) and, in England, NHS England commissioning policies for severe and complex obesity services.

Standard eligibility criteria include:

• A body mass index (BMI) of 40 kg/m² or above, or

• A BMI of 35–39.9 kg/m² with a significant obesity-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea

• Evidence that non-surgical interventions (dietary, pharmacological, and behavioural) have been tried and have not achieved or maintained adequate weight loss

• Commitment to long-term follow-up and lifestyle changes

• Fitness for general anaesthesia and major surgery

Additional NICE CG189 provisions:

• Adults with a BMI of 35 kg/m² or above and recent-onset type 2 diabetes (typically diagnosed within the past ten years) should be offered expedited assessment for bariatric surgery, given the strong evidence for metabolic benefit.

• Consideration at BMI 30–34.9 kg/m² is appropriate for adults with recent-onset type 2 diabetes where non-surgical measures have been insufficient.

• For adults of Asian family background, NICE recommends applying BMI thresholds that are 2.5 kg/m² lower than the standard thresholds when considering interventions, including surgery, reflecting differing metabolic risk profiles.

In England, patients are typically referred through a structured pathway: Tier 3 specialist weight management services (which provide intensive dietary, psychological, and medical support) before progressing to Tier 4 bariatric surgery services. Access and referral pathways vary across the devolved nations — NHS Scotland, NHS Wales, and Health and Social Care in Northern Ireland each operate their own commissioning and referral structures; patients should discuss local arrangements with their GP.

Certain groups may require additional consideration or may not be suitable for sleeve gastrectomy specifically. Patients with significant pre-existing GORD or Barrett's oesophagus may be better served by an alternative bariatric procedure. Those with severe psychiatric illness, active substance misuse, or conditions that impair surgical healing require careful multidisciplinary evaluation before proceeding.

All patients referred for bariatric surgery should undergo a comprehensive assessment by a multidisciplinary team (MDT), which typically includes a bariatric surgeon, specialist dietitian, psychologist or psychiatrist, and specialist nurse. Patients considering surgery through private providers should ensure the same standard of MDT assessment is in place, as this is a fundamental patient safety requirement endorsed by BOMSS and the Royal College of Surgeons of England.

Long-Term Outcomes and What to Expect After Surgery

Most patients lose 50–70% of excess body weight within 12–18 months, with evidence of sustained improvement in type 2 diabetes, blood pressure, and quality of life, provided lifelong dietary and supplementation commitments are maintained.

The long-term outcomes following gastric sleeve surgery are generally positive for appropriately selected patients, with evidence from the NBSR and peer-reviewed literature supporting sustained weight loss and meaningful improvements in obesity-related health conditions over five to ten years.

On average, patients can expect to lose approximately 50–70% of their excess body weight within the first 12–18 months following surgery. Many patients maintain significant weight loss at five years, though outcomes vary depending on adherence to dietary guidance, physical activity levels, and access to psychological support.

Health benefits commonly reported include:

• Remission or significant improvement of type 2 diabetes — remission rates vary depending on duration of diabetes, baseline glycaemic control, and the procedure performed; observational studies and NBSR data suggest remission in approximately 50–60% of patients with sleeve gastrectomy at one to three years, though rates may be lower in those with longer-standing or more complex diabetes

• Reduction in blood pressure and cardiovascular risk

• Improvement in joint pain and mobility

• Enhanced quality of life and mental wellbeing

• Observational evidence suggests a reduction in the risk of certain obesity-related cancers, though this is based on registry and cohort data rather than randomised controlled trials

Important longer-term considerations:

• Nutritional supplementation and monitoring: Lifelong supplementation is essential. In line with BOMSS guidance, this typically includes a complete multivitamin and mineral supplement, vitamin D with or without calcium, and iron where indicated, with B12 managed per local protocol. Blood tests should be performed at 3, 6, and 12 months post-surgery, then annually.

• Pregnancy planning: Women of childbearing age are advised to delay conception for at least 12–18 months after surgery, when weight loss is most rapid and nutritional status may be less stable. Contraceptive effectiveness may be affected in the early postoperative period; discuss this with your surgical team or GP. Folic acid and other supplements are particularly important if pregnancy is planned.

• Alcohol: Sensitivity to alcohol may increase after surgery. There is also an elevated risk of alcohol use disorder following bariatric procedures; patients should be counselled accordingly.

• Bone health: Bariatric surgery can affect bone density over time. Adequate vitamin D and calcium intake, alongside monitoring, is important for long-term bone health.

• Gallstones: As noted above, rapid weight loss increases gallstone risk; discuss prophylaxis options with your team.

Surgery is a tool, not a cure. Long-term success depends heavily on sustained behavioural change, including adopting a nutrient-dense diet, eating slowly, avoiding high-calorie liquids, and engaging in regular physical activity.

Follow-up care on the NHS typically includes regular appointments with the bariatric team for at least two years post-surgery, in line with NHS England service specifications, with ongoing GP involvement thereafter. Patients experiencing significant weight regain, nutritional symptoms, or persistent reflux should seek review from their surgical team or GP without delay.

NICE Guidelines and Making an Informed Decision

NICE CG189 supports bariatric surgery for severe obesity within a specialist multidisciplinary setting, with expedited assessment recommended for adults with a BMI of 35 kg/m² or above and recent-onset type 2 diabetes.

NICE Clinical Guideline CG189 provides the primary framework for the assessment and management of obesity in the UK, including the role of bariatric surgery. NICE recommends that surgery should be considered as a treatment option for adults with severe obesity when non-surgical approaches have been insufficient, and that it should be delivered within a specialist multidisciplinary setting with robust follow-up arrangements in place.

NICE CG189 also recommends that adults with a BMI of 35 kg/m² or above and recent-onset type 2 diabetes (typically diagnosed within the past ten years) should be offered expedited assessment for bariatric surgery, given the strong evidence for metabolic benefit in this group. Furthermore, bariatric surgery should be considered for adults with a BMI of 30–34.9 kg/m² who have recent-onset type 2 diabetes where non-surgical measures have not been sufficient. For adults of Asian family background, these BMI thresholds are reduced by 2.5 kg/m².

Access to NHS bariatric surgery varies across the UK. In England, commissioning is managed by integrated care boards (ICBs) in line with NHS England's service specification for severe and complex obesity. In Scotland, Wales, and Northern Ireland, commissioning and referral arrangements are managed by the respective devolved health services; patients should discuss local access with their GP.

Making an informed decision about gastric sleeve surgery involves weighing the potential benefits against the risks in the context of an individual's overall health, lifestyle, and personal goals. Key questions to discuss with your surgical team include:

• What are the realistic weight-loss expectations for my situation?

• How will my existing medical conditions affect surgical risk?

• What nutritional and lifestyle commitments will I need to maintain long-term?

• Is sleeve gastrectomy the most appropriate procedure for me, or should alternatives be considered?

Patients are encouraged to access information from reputable sources including the NHS website (nhs.uk), NICE guidelines (nice.org.uk/guidance/cg189), and the British Obesity and Metabolic Surgery Society (BOMSS) patient resources (bomss.org). Seeking a second opinion is entirely reasonable and supported within NHS practice.

If you experience any unexpected symptoms or concerns related to a surgical device following your procedure, these can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Ultimately, when performed in the right patient by an experienced team within an accredited service, gastric sleeve surgery is considered a safe and effective intervention for the management of severe obesity, supported by NICE, NHS England, and BOMSS.

Frequently Asked Questions